Roche, Five Prime Therapeutics to Develop CDx Assays for Immuno-Oncology Drug Trials

May 31, 2018

|

NEW YORK (GenomeWeb) – Clinical-stage biotech Five Prime Therapeutics said today that it is collaborating with Roche to develop immunohistochemistry companion diagnostic assays for use with Five Prime’s investigational drug candidates, bemarituzumab, an anti-FGFR2b antibody, and FPA150, a B7-H4 antibody.

Financial terms of the agreement were not disclosed.

The firms are collaborating to develop, validate, and commercialize a tissue-based IHC CDx assay to help identify patients whose tumors overexpress the FGFR2b protein and are eligible for treatment with bemarituzumab.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

For In Vitro Diagnostic Materials: Efficacy vs. Thimerosal and Sodium Azide

Development of a Quantitative Lateral Flow Test Using Estapor Europium Microspheres

Performance of Estapor Microspheres and Hi-Flow Plus Membranes in a Lateral Flow Assay for Human Chorionic Gonadotropin (hCG)

ProClin 300 Preservative: An In-Depth Technical Analysis

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr

29

Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May

13

Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May

18

Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.

Menu

Roche, Five Prime Therapeutics to Develop CDx Assays for Immuno-Oncology Drug Trials

To read the full story....

Breaking News

PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

Ethos Labs, Agena Biosciences Partner on SARS-CoV-2 Variant Identification

Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

Australian Firm AnteoTech Obtains CE Marking for COVID-19 Antigen Test, Reader

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

Featured White Papers

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

DiaSorin to Acquire Luminex for $1.8B

Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

Sponsorships